Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer
Authors
Keywords
-
Journal
MODERN PATHOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-11-25
DOI
10.1038/s41379-020-00710-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
- (2018) Karina Kulangara et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis
- (2018) Wei-fa Yang et al. ORAL ONCOLOGY
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors
- (2017) Charles Caldwell et al. Scientific Reports
- Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1
- (2016) Marisa Dolled-Filhart et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
- (2016) C.-Y. Ock et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients
- (2016) Hye Ryun Kim et al. Scientific Reports
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
- (2015) Luisa Carbognin et al. PLoS One
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
- (2012) D. S. Chen et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More